0HQ1.LSE Azenta
- Market cap
- -
- P/E
- 1.2x
- P/B
- -
- ROE
- -15.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0HQ1.LSE undervalued?
Graham numberThe Graham number of Azenta cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Azenta fundamental analysis
No fundamental analysis for Azenta yet.
Azenta stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables…
Full company profileAzenta financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Azenta annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 560M | 527M | 632M | 781M | 389M | 514M | 555M | 665M | 656M | 594M | 606M |
| Gross Profit | 187M | 186M | 227M | 292M | 145M | 215M | 231M | 273M | 237M | 270M | 264M |
| Operating Income | 19.5M | 18.2M | 34.4M | 55.1M | -27.5M | 3.60M | -24.0M | -82.2M | -72.9M | -11.3M | -30.0M |
| EBITDA | 32.2M | 42.1M | 66.7M | 86.1M | 28.1M | 9.94M | 48.4M | 55.2M | -76.6M | 54.1M | 30.2M |
| Net Income | -69.5M | 62.6M | 117M | 28.8M | 64.9M | 111M | -429M | -12.9M | -164M | -55.8M | -232M |
| EPS | -1.01 | 0.89 | 1.64 | 0.40 | 0.88 | 1.49 | -5.73 | -0.19 | -3.09 | -1.21 | -5.12 |
| Balance Sheet | |||||||||||
| Total Assets | 686M | 767M | 1.10B | 1.52B | 1.56B | 1.82B | 3.72B | 2.89B | 2.10B | 2.06B | 1.88B |
| Total Liabilities | 132M | 159M | 377M | 377M | 346M | 494M | 353M | 351M | 331M | 334M | 366M |
| Shareholders' Equity | 554M | 608M | 718M | 1.14B | 1.21B | 1.33B | 3.36B | 2.53B | 1.77B | 1.73B | 1.51B |
| Cash & Short-term Investments | 85.1M | 102M | 244M | 339M | 254M | 235M | 1.95B | 1.02B | 464M | 341M | 328M |
| Total Debt | - | - | 196M | 53.8M | 74.8M | 100M | 56.3M | 72.0M | 70.7M | 111M | 54.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 39.5M | 96.2M | 74.0M | 90.9M | 37.9M | 150M | -466M | 17.5M | 50.3M | 72.2M | 46.0M |
| Capital Expenditure | 12.8M | 12.9M | 12.8M | 23.9M | 39.9M | 52.8M | 77.4M | 39.4M | 37.4M | 33.9M | 27.0M |
| Free Cash Flow | 26.7M | 83.3M | 61.2M | 67.0M | -2.06M | 97.1M | -543M | -21.9M | 12.9M | 38.3M | 19.0M |
| Ratios | |||||||||||
| ROE | -12.5% | 10.3% | 16.2% | 2.5% | 5.3% | 8.4% | -12.8% | -0.5% | -9.3% | -3.2% | -15.3% |
| ROA | -10.1% | 8.2% | 10.6% | 1.9% | 4.2% | 6.1% | -11.5% | -0.4% | -7.8% | -2.7% | -12.3% |
| Net Profit Margin | -12.4% | 11.9% | 18.5% | 3.7% | 16.7% | 21.6% | -77.2% | -1.9% | -25.0% | -9.4% | -38.2% |
| Debt to Equity | - | - | 0.27x | 0.05x | 0.06x | 0.08x | 0.02x | 0.03x | 0.04x | 0.06x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Azenta dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 7.49M | 0.10 | - |
| 2021 | USD 29.7M | 0.40 | 26.8% |
| 2020 | USD 29.5M | 0.40 | 45.5% |
| 2019 | USD 28.9M | 0.40 | 100.3% |
| 2018 | USD 28.3M | 0.40 | 24.3% |
| 2017 | USD 27.9M | 0.40 | 44.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Azenta
- Insiders 1.33%
- Institutions 98.67%
- Public & others 0.00%
- Free float 38.9M
Azenta company profile
- Company name
- Azenta
- Ticker
- 0HQ1.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 2,900
- Fiscal year end
- September
- Address
- 200 Summit Drive, Burlington, MA, United States, 01803
- Phone
- 888 229 3682
- Website
- azenta.com
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Azenta management
10- Dr. Martin D. Madaus D.V.M., Ph.D.Interim President, CEO & Director · born 1960
- Mr. Lawrence Y. LinExecutive VP & CFO · born 1977
- Mr. Ephraim StarrSenior VP, General Counsel & Corporate Secretary · born 1972
- Ms. Olga PirogovaSenior VP & Chief HR Officer · born 1974
- Dr. Ginger Zhou Ph.D.Advisor · born 1977
- Mr. Erik J. BelloVice President, Chief Accounting Officer & Principal Accounting Officer
- Mr. Michael PauloVP, Chief Information & Digital Officer
- Ms. Yvonne PerronVice President of Financial Planning & Analysis and Investor Relations
- Mr. William E. Martin IIISenior Vice President & President of Multiomics · born 1975
- Dr. Andrea O'Hara Ph.D.Strategic Technical Specialist of Azenta Life Sciences